Early stage NSCLC
108TiP - A multi-center, prospective, randomized controlled clinical trial: Comparison between wedge resection and segmentectomy in the surgical treatment of ground glass opacity-dominant stage IA non-small cell lung cancer
Authors
- Lunxun Liu (CN)
- Hu Liao (CN)
Presenter
- Lunxun Liu (CN)
Advanced NSCLC
141PD - A prospective study of molecular testing status in the EGFR mutation positive NSCLC patients with disease progression during EGFR TKI treatment (REMEDY study)
Authors
- Kuninobu Kanai (JP)
- Nobuyuki Yamamoto (JP)
- Naoyuki Nogami (JP)
- Shinji Atagi (JP)
- Hideo Saka (JP)
- Naoki Tashiro (JP)
- Takashi Seto (JP)
Presenter
- Kuninobu Kanai (JP)
Advanced NSCLC
175P - A prospective, randomized, double-blind study of pre-chemotherapy hydration with or without mannitol to prevent renal toxicity in non-small cell lung cancer (NSCLC) patients receiving cisplatin-gemcitabine chemotherapy
Authors
- Nattiya Thavornpattanpong (TH)
Presenter
- Nattiya Thavornpattanpong (TH)
Early stage NSCLC
104P - Adjuvant chemotherapy may improve prognosis in surgically resected stage I NSCLC with lymphovascular invasion
Authors
- Shuyuan Wang (CN)
- Jianlin Xu (CN)
- Fangfei Qian (CN)
- Wenjia Yang (CN)
- Bo Zhang (CN)
- Jie Qian (CN)
- RONG Qiao (CN)
- Baohui Han (CN)
Presenter
- Shuyuan Wang (CN)
Advanced NSCLC
133PD - Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) for non-small cell lung cancer (NSCLC): A systematic review and meta-analysis
Authors
- Jacques Raphael (CA)
- Mark Vincent (CA)
- Gabriel Boldt (CA)
- Prakeshkumar Shah (CA)
- George Rodrigues (CA)
- Phillip Blanchette (CA)
Presenter
- Jacques Raphael (CA)
Advanced NSCLC
158P - Afatinib in patients with EGFR mutation-positive (EGFRm+) NSCLC harbouring uncommon mutations: Overview of clinical data
Authors
- Angela Märten (DE)
- Nobuyuki Yamamoto (JP)
- Chong-Jen Yu (TW)
- Sai-Hong I. Ou (US)
- Caicun Zhou (CN)
- Yi-Long Wu (CN)
Presenter
- Angela Märten (DE)
Advanced NSCLC
198TiP - Afatinib plus EGF pathway targeting immunization (EGF-PTI) as first line therapy for EGFR mutant NSCLC: The EPICAL study
Authors
- Niki Karachaliou (ES)
- Andres Cardona Zorrilla (CO)
- Delvys Rodríguez-Abreu (ES)
- Manolo Cobo Dols (NA)
- Noemi Reguart Aransay (ES)
- Santiago Viteri (ES)
- JORDI Codony-Servat (ES)
- Miguel Angel Molina-Vila (ES)
- Erik D'Hondt (BE)
- Rafael Rosell (ES)
Presenter
- Niki Karachaliou (ES)
Tumour biology and pathology
27P - ALK immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients
Authors
- Giulio Metro (IT)
- Rita Chiari (IT)
- Diana Giannarelli (IT)
- Angelo Sidoni (IT)
- Guido Bellezza (IT)
Presenter
- Giulio Metro (IT)
Advanced NSCLC
/thumbnails/0.png)
165P - Analysis of our experience of ROS-1 patients in advanced NSCLC
Authors
- Nikhil Pande (IN)
- Amit Joshi (IN)
- Vanita Noronha (IN)
- Vijay Patil (IN)
- Abhishek Mahajan (IN)
- Kumar Prabhash (IN)
Presenter
- Nikhil Pande (IN)
Tumour biology and pathology
31P - Analysis of ROS1 rearrangement non-small cell lung cancer cell blocks from pleural effusion
Authors
- Wen-xian Wang (CN)
- Chunwei Xu (CN)
- Wu Zhuang (CN)
- Yuwang Tian (CN)
- Jianping Xu (CN)
- Meiyu Fang (CN)
- Yanping Chen (CN)
- Gang Chen (CN)
- Tangfeng Lv (CN)
- Yong Song (CN)
Presenter
- Wen-xian Wang (CN)
Advanced NSCLC
173P - Apatinib plus S-1 showes encouraging response in advanced non-small-cell lung canceras as laterline chemotherapy
Authors
- Zhiyong Wu (CN)
- Jianyu Wu (CN)
Presenter
- Zhiyong Wu (CN)
Advanced NSCLC
190P - Are neutrophil-to-lymphocyte ratio (NLR) and neutrophil count percentage (NCP) predictors of nivolumab outcome and toxicity in NSCLC?
Authors
- Jacobo Rogado (ES)
- Vilma Pacheco Barcia (ES)
- Patricia Toquero (ES)
- Beatriz Vera (ES)
- Rebecca Mondejar (ES)
- Nuria Romero Laorden (ES)
- Ana Isabel Ballesteros Garcia (ES)
- Olga Donnay (ES)
- Ramon Colomer Bosch (ES)
- José Miguel Sánchez-Torres (ES)
Presenter
- Jacobo Rogado (ES)